insitro has landed another big biopharma partnership, signing a five-year collaboration with Bristol Myers Sqibb to develop therapies for amyotrophic lateral sclerosis (ALS) and frontotempo
Roger Perlmutter has brought a seven-year stint as head of R&D at Merck & Co/MSD to a close, jumping ship to take on an advisory role at machine-learning specialist Insitro.
Less than a year after coming out of stealth mode with a $65 million first-round last year, artificial intelligence specialist Insitro has already signed its first biopharma partner.
